Suppression of fentanyl-induced cough. A priming dose of intravenous dexmedetomidine–magnesium sulfate: A double blind, randomized, controlled study

Peer review under responsibility of Egyptian Society of Anesthesiologists.

Figures & data

hart 1 Flowchart of participants’ progress through the phasis of the trial.

able 1 Demographic data in four groups. Values are in means ± SD.

Demographics	Group S (n = 50)	Group D (n = 50)	Group M (n = 50)	Group D + M (n = 50)	P
Age (years)	40.3 ± 11.1	39.8 ± 12.3	40.9 ± 10.9	38.6 ± 14.1	0.63
Gender male/female	27/23	26/24	22/28	24/26	0.75
Weight (kg)	80.9 ± 8.4	78.5 ± 5.3	79.3 ± 1.2	80.6 ± 4.3	0.76
Height (cm)	161.8 ± 7.2	165.6 ± 5.5	162.4 ± 8.1	164.3 ± 4.6	0.81
ASA class I/II	46/4	43/7	42/8	47/3	0.32

No significant difference was detected in this table.

able 2 Incidence, the onset time and severity of cough after intravenous fentanyl administration. Values are in mean ± SD or number (%).

Group	Incidence of cough (%)	Onset(s)	Severity of cough (%)
			Mild	Moderate	Sever
Group S	19(38%)	18.6 ± 2.9	8(42.1%)	5(26.3%)	6(31.6%)
Group D	8(16%)^⁎ [p = 0.02]	19.8 ± 3.4	3(37.5%)	3(37.5%)	2(25%)
Group M	14(28%) [p = 0.32]	19.0 ± 1.8	6(42.9%)	4(28.6%)	4(28.6%)
Group D ± M	0(0%)^⁎ [p < 0.001]	–	–	–	–

#x204E; P is significant if ⩽ 0.05 at confidence interval 95% (in comparison with group S).